Our specialist multi-disciplinary LIFE SCIENCES team advises businesses at all stages of the medicines supply chain

Life Sciences

Our multi-disciplinary life sciences team advises a wide range of clients in the life sciences sector including some of the world’s largest pharmaceutical companies, biotech companies, healthcare providers and medical devices manufacturers. 

We advise life sciences companies at all stages of the medicines supply chain on the full range of legal issues affecting them including competition, regulatory and compliance, intellectual property including patents and trade marks, product life cycle, clinical trial agreements, collaboration, licensing and other commercial transactions.

We also have extensive experience of advising on acquisitions in the life sciences area and in advising banks and financial institutions with an interest in this space.

 

 

  • Intellectual Property

    Intellectual property rights are of vital importance to companies in the life sciences sector and are often the most valuable assets of the business. We can help companies in the life sciences and healthcare space to effectively and efficiently protect and exploit their intellectual property rights.

    We have extensive experience of handling litigation at all levels of the UK courts, as well as managing multi-jurisdiction disputes and working with leading IP practitioners in the overseas territories in which our clients are active. However, an equally important aspect of our work is advising on the effective protection, use and licensing of IP rights to maximise our clients’ commercial advantage and prevent disputes arising. Our team advises on the full range of contentious and non-contentious intellectual property including patent litigation and licensing, and trade secrets litigation.

  • Commercial Agreements

    Our Commercial team has extensive experience and in-house expertise of the legal issues that affect life sciences and healthcare companies on a daily basis.

    Our experience extends to generics, animal health, eye care, innovators, manufacturers, vaccines, medical devices as well as biotech and delivery systems. In particular, we work closely with in-house life science and pharmaceutical teams and regularly assist with the drafting, negotiation and termination of commercial agreements. These include NDAs, clinical trials, joint working agreements and collaboration arrangements, sales or purchase terms, rebates, sales of marketing authorisations. We also advise on manufacturing and supply contracts, warehousing and logistics, standard template agreements, appointment of field sales teams, outsourcing and procurement and licensing and marketing contracts.

  • Competition and EU law

    Ensuring compliance with competition law should be a key priority of any life sciences and healthcare business.  Because of the importance of the sector to the global economy, and the dynamic nature of life sciences markets, the sector is, and will continue to be, a high priority for enforcement.  Competition law can also provide an opportunity for businesses to ensure that competitors play fair, and can result in substantial damages being awarded for infringements.

    Our competition team is hugely experienced in the life sciences sector.  We have many years’ experience of working with regulators and companies in this area.  Experience includes advisory work, implementing compliance training, acting in relation to government investigations and dawn raids and carrying out litigation including judicial review of government policy.

  • Regulatory

    Pharmaceutical and biotechnology businesses are subject to a huge range of regulations.  In addition to general regulations (e.g. anti-bribery and corruption, competition law and data privacy), life sciences businesses are required to comply with a range of sector specific regulations and voluntary schemes.

    We have experience of advising on both general and sector specific regulations impacting life sciences businesses.  We have provided compliance training and have assisted businesses on issues as they arise.  These include government investigations, including dawn raids, issues arising in the context of commercial and corporate transactions and day to day issues facing businesses.

  • Dispute Resolution

    We have considerable experience of handling disputes arising for clients in the life sciences sector over many years. We often work closely with the client’s in-house team and have developed a detailed understanding of the sector and what is important for their businesses.

    Our work involves advice on issues as they emerge, mediation, litigation and arbitration.  Where urgent situations arise we have considerable experience of seeking injunctive relief to prevent damage or loss.

    In addition to disputes arising under licensing, supply and development agreements, we also deal with other issues such as product recall and claims arising. We also act for life sciences clients in relation to construction and engineering disputes.  

    Examples of our experience include:

    - Successfully representing a multinational pharmaceutical company relating to a multi-million pound cross-border fraud to obtain freezing and seizure orders

    - Acting for pharmaceutical clients in relation to dawn raids by the SFO on their UK offices

    - Acted for an international life sciences company in an ICC arbitration against a foreign life sciences company 

  • Corporate and Banking

    We have experience of advising both buyers and sellers of companies and businesses in the pharmaceutical, life sciences and healthcare sectors. This includes management teams on leveraged transactions.

    We have advised on equity fundraisings including private equity and development capital transactions and debt transactions including traditional senior bank debt but also warrants and other forms of finance.

  • Data Protection

    Data protection issues are now high profile and often come under the spotlight.  We act for organisations looking to resist Freedom of Information requests or dealing with Data Protection or data licensing issues. The arrival of the General Data Protection Regulations means that we are helping many organisations to prepare for its impact. Our team is well versed in data protection issues and has in-house experience for a worldwide major pharmaceutical company on data protection issues.

    Our advice covers data licensing, dealing with sensitive personal data, data breaches, appointment of data processors in outsourced IT and services, transfers of personal data outside the EEA, making and resisting data subject access requests and freedom of information requests. We draft privacy and cookies notices, advise on notifications to the Information Commissioner’s office and assist in the preparation of policies and standard operating procedures including for surveillance and interception of emails and privacy impact assessments.

    We work closely with our international colleagues on trans-border transactions and provide advice on implementation of the General Data Protection Regulations.

Our experience

  • Advising the UK stakeholders responsible for UK’s overall implementation of the Falsified Medicines Directive
  • Advising an international pharmaceutical company on complex patent, regulatory and data protection issues
  • Assisting a global pharmaceutical company on successful Judicial Review of Home Office policy
article

Developments in the online sale of pharmaceuticals in the EU

In this article, Gustaf Duhs, Partner and Head of Competition and Regulatory Law at Stevens & Bolton LLP, sets out a brief summary of the recent case before the CJEU relating to fixed pharmacy prices involving online pharmacy DocMorris and what this...

Read more
article

New voluntary capped costs pilot for claims up to £250,000

Further to our May 2017 update on fixed recoverable costs, a new voluntary capped costs pilot scheme is soon to be introduced in the High Court for claims up to £250,000 proceeding in the London Mercantile Court or the Mercantile, Chancery or...

Read more
article

Controlling the Drugs Bill

The NHS drugs bill (reportedly over £15.2 billion in 2015-16) recently came into sharp focus following news reports highlighting dramatic price increases for longstanding generic drugs. Examples frequently cited include the anti-epilepsy drug...

Read more
article

Store Twenty One is the latest casualty of the retail sector as company enters liquidation

The West Midlands company, Grabal Alok (UK) Limited, better known as ‘Store Twenty One’ entered liquidation on 11 July 2017 on the making of a winding up order by the High Court. This is the latest casualty in the retail sector amongst...

Read more
article

Out of tune?

The development of streaming services such as Spotify and Tidal, alongside a society that actively shares content across social media, has changed the landscape for those working in the music industry. In 2017, streaming is projected to overtake physical...

Read more
article

Changes to the Subject Access Code of Practice

The Information Commissioner’s Office has updated its Subject Access Code of Practice to reflect two recent Court of Appeal judgements which examined the obligations to comply with a subject access request. Background The Data Protection Act 1998...

Read more
article

Should a tribunal consider a Claimant's long-term future loss of earnings if they did not expressly assert it?

In the case of Small v Shrewsbury and Telford Hospitals NHS Trust , the Court of Appeal found that a Claimant was entitled to long-term loss of earnings even though they did not advance such a claim. This was in the context of a whistleblowing claim where...

Read more
article

Data Protection and Launch of New Fundraising Preference Service

On 6 July, the Fundraising Regulator launched the Fundraising Preference Service (FPS), a new scheme which enables members of the public to request that selected charities stop sending direct marketing communications to them. The FPS allows members of the...

Read more
article

Amazon, Brands and the War on Counterfeits: A Guide to Protecting your Rights

Given its extensive media coverage, few of you will have let the third annual Amazon Prime Day pass you by unnoticed.  However, Amazon’s success is down to more than just flash sales and impressive marketing campaigns.   From its...

Read more
article

Could a lender owe a higher duty of care to its customers beyond simply conveying the correct information?

Could a lender owe a higher duty of care to its customers rather than one simply not to misstate facts, even where no advisory relationship exists? A recent case, Philip Thomas, Helen Thomas v Triodos Bank NV [2017] EWHC 314 (QB), has highlighted that,...

Read more
article

The Competition Appeals Tribunal finds that the Law Society abused its dominant market position

The Competition Appeals Tribunal (the “CAT”) found in its ruling of 26 May 2017 that the Law Society of England and Wales (the “Law Society”) abused its dominant market position by requiring law firms accredited under its Conveyancing...

Read more
article

Aviation's cyber conundrum

Cyber crime and threats loom in the aviation industry. Cyber-crime and cyber threats are very much a topic du jour and was certainly a talking point at the recent Paris Air Show I attended. Following allegations of interference in recent elections around...

Read more
article

High Court implies public law limitations on a contractual discretion

In a case which may surprise (and possibly alarm) lenders and their advisers, the recent decision of the High Court in Watson v Watchfinder.co.uk [2017] EWHC 1275 illustrates the potential pitfalls for commercial parties with a (seemingly absolute)...

Read more
article

Article 50: what next for international contracts?

The UK government set the clock ticking as it served notice of departure from the European Union (EU) on 29 March, with negotiations likely to start in earnest soon after the general election on 8 June. As the nation braces itself for what could be a bumpy...

Read more
article

European Commission fines Google 2.42 billion Euros for breaching EU competition law by abusing its dominant position

The European Commission (the “Commission”) has fined Google €2.42 billion, the largest EU fine imposed on a company for infringing EU competition law. The Commission considers that Google abused its dominant position as a search engine by...

Read more
article

Location, location, location... European Medicines Agency Brexit guidance published

With the uncertainty that comes with considering the impact of the “B” word, guidance has recently been published by the European Commission and the European Medicines Agency (EMA) with regard to centrally authorised medicinal products for human...

Read more
article

Important changes to the People with Significant Control (PSC) regime

On Monday 26 June the Information about People with Significant Control (Amendment) Regulations 2017 (“Regulations”) came into force.  The Regulations modify and extend the existing national PSC register measures in order to complete the...

Read more
article

Discrimination risk when providing references

The recent tribunal case of Mr P Mefful v Citizens Advice Merton and Lambeth serves as a reminder of the risks when giving references to prospective employers. The tribunal found that an employee was discriminated against by their former employer after the...

Read more
article

International Commercial Transactions, Franchising, and Distribution - The Year in Review

Nicola Broadhurst, Head of Franchising, reviews the Modern Slavery Act in the American Bar Association's Section of International Law annual publication. This article reviews 2016 legal developments to the field of international...

Read more
article

Recast European Insolvency Regulation (2015) comes into effect - 26 June 2017

The recast European Insolvency Regulation (EIR) applies to all insolvencies commencing on or after 26 June 2017. It replaces the EC Regulation on Insolvency Proceedings (2000)(the “EC Regulation”), although the EC Regulation will still apply to...

Read more
article

Queen's Speech confirms UK will implement GDPR

The Queen’s Speech yesterday shed further light on how the General Data Protection Regulation (GDPR) will be implemented in the UK.  The speech confirmed that the UK would implement the GDPR as well as the new European Directive on processing by...

Read more
article

6 July share schemes reporting deadline - Time to act

This briefing discusses HMRC’s upcoming 6 July deadline for certain filings relating to share schemes and other employment-related securities. HMRC will not issue reminders for these reporting requirements. Even if there has been no activity for the...

Read more
article

Non-compete clause: consideration given to expectations of future promotions when determining reasonableness

The recent High Court case of Egon Zehnder Ltd v Mary Caroline Tillman has found that, although the reasonableness of a non-compete clause should be assessed at the time the contract is entered into, the parties’ expectations of future promotions...

Read more
article

Construing limitation and exclusion of liability clauses in construction contracts

Persimmon Homes Ltd & Ors v Ove Arup & Partners Ltd [2017] EWCA Civ 373 Case Summary A property development consortium comprising Persimmon Homes, Taylor Wimpey and BDW brought a claim for damages against Ove Arup (a civil engineering firm) for...

Read more
article

Dismissing a whistleblower: is the employer's belief that the disclosure is not protected relevant?

The recent Court of Appeal case of Dr Beatt v Croydon Health Services NHS Trust has found that, in a whistleblower dismissal case, the question of whether a disclosure is protected is an objective one. Facts Dr Beatt, a consultant cardiologist, was...

Read more
article

New UK law to control generic drug prices - implications for pharma

In an article which first appeared in Pharmaphorum , Charlotte Tillett and Astrid Arnold outline the aims and implications of the new legislation. Drug pricing legislation update The UK’s Health Service Medical Supplies (Costs) Act 2017 obtained...

Read more
article

Corporate Borrowers: PLC checklist for negotiating a debenture

Head of Banking and Finance, Jonathan Porteous, and Senior Associate, Matthew Padian, have prepared a checklist for leading legal publisher, Practical Law, covering the key points for corporate borrowers to consider when granting security over assets...

Read more
article

Beds and Sheds - a viable solution for retailers?

Howard Lupton, examines the need for joint ventures between industrial and residential developers to keep up with the demand for warehousing and homes within the M25.  Retailers need more last-mile logistics capacity within the M25, but will the market...

Read more
article

Winding up petitions rarely appropriate to recover sums due under a construction contract

In the recent case of Breyer Group plc v RBK Engineering Ltd [2017] EWHC 1206 (Ch), the High Court confirmed that winding up proceedings will rarely be an appropriate forum to recover sums due under a construction contract, particularly in circumstances...

Read more
article

Disability discrimination: what happens if an employee's sick leave results in the identification of a redundancy situation?

In the recent case of Charlesworth v Dransfields Engineering Services Ltd , the Employment Appeal Tribunal (“EAT”) has concluded that, where an employee’s sickness absence allows his employer to identify that his role is no longer needed...

Read more
  • Page 1 of 10

Search our site